Lexicon Pharmaceuticals Inc (LXRX)

O firmie

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.